Evidence map›Paper›PMID 38276680›Full record

ArticleVaccines2024

Comparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model.

Kyu-Ri Kang, Ji-Ahn Kim, Gyu-Won Cho, Han-Ul Kang, Hyun-Mi Kang, Jin-Han Kang, Baik-Lin Seong, Soo-Young Lee

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Safety assessments of recombinant DTaP vaccines developed in South Korea.Clinical and experimental vaccine research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kyu-Ri KangThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0001-9135-1890
Ji-Ahn KimThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Gyu-Won ChoThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Han-Ul KangThe Interdisciplinary Graduate Program in Integrative Biotechnology, Yonsei University, Incheon 21983, Republic of Korea.ORCID 0009-0007-1171-8316
Hyun-Mi KangThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Jin-Han KangThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Baik-Lin SeongDepartment of Microbiology and Immunology, College of Medicine, Yonsei University, Seoul 03722, Republic of Korea.ORCID 0000-0002-7301-082X
Soo-Young LeeThe Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-5354-3135
The Catholic University of Korea Seoul St. Mary's Hospital · KRYonsei University · KRThe Catholic University of Korea Bucheon St. Mary's Hospital · KR

Funding

Korea Health Industry Development Institute HV20C0146
6 · The paper itself

Abstract

Since the 2000s, sporadic outbreaks of whooping cough have been reported in advanced countries, where the acellular pertussis vaccination rate is relatively high, and in developing countries. Small-scale whooping cough has also continued in many countries, due in part to the waning of immune protection after childhood vaccination, necessitating the development of an improved pertussis vaccine and vaccination program. Currently, two different production platforms are being actively pursued in Korea; one is based on the aP (acellular pertussis) vaccine purified from

Indexed as

DTaP vaccineefficacy of acellular pertussis vaccinemouse studyPTx neutralizationrecombinant aP vaccine

Identifiers

PMID38276680
PMCPMC10818713
OpenAlexW4391102694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.